Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. - Wikidata - awgldk - TriplyDB

Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

http://www.wikidata.org/entity/Q48379750

about

Mycobacterial and nonbacterial pulmonary complications in hospitalized patients with human immunodeficiency virus infection: a prospective, cohort study Comparison of SCH 39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes Polyamine depletion and growth inhibition of Cryptococcus neoformans by alpha-difluoromethylornithine and cyclohexylamine Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats Interactions of posaconazole and flucytosine against Cryptococcus neoformans Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates Potent antifungal effects of a new derivative of partricin A in a murine model of cerebral cryptococcosis Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.Chronic meningitis in Thailand. Clinical characteristics, laboratory data and outcome in patients with specific reference to tuberculosis and cryptococcosis.Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.Ferrous iron uptake in Cryptococcus neoformans Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations Interactions between triazoles and amphotericin B against Cryptococcus neoformans.Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3 Effects of voriconazole on Cryptococcus neoformans.Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin.In vitro antifungal susceptibility testing.Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants.Cholangitis in the acquired immunodeficiency syndrome: report of two cases and review of the literature.Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells.HIV and the central nervous system.AIDS related opportunistic infections, going but not gone.The contribution of melanin to microbial pathogenesis.Fluconazole penetration in cerebral parenchyma in humans at steady state Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms.Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds.Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro Risk factors for invasive Cryptococcus neoformans diseases: a case-control study Cranial vena cava syndrome secondary to cryptococcal mediastinal granuloma in a cat Cardiac tamponade in patients with human immunodeficiency virus disease.

P2860

Q24806176-A14407B9-60C9-4A48-B99A-CD46DB174088 Q28319936-9F68D31A-F79E-4F91-8866-70660DE88667 Q28328605-A8B2FCED-ABE6-4691-AB93-05316A04A46E Q28332185-2AF07969-9820-4D0D-BA65-96F82CAF6C8F Q28333669-B35694F6-762E-46CD-AFF2-D2887AD6C066 Q28362562-F82F6D8F-43B9-496E-85F0-7B8A7009847F Q28366062-A81C1B21-4DA6-4387-B976-97F30BEF48C9 Q28367448-6F7974C3-1CC8-4DC3-BD81-D9C1A1366771 Q28373675-6329BA47-9F36-46CB-ADB8-BA4930A80D60 Q28379505-BD855B67-9BC5-486C-A37C-972FF09E5D67 Q30424017-C5B19149-98C4-4DC6-B26F-AB7C5A3848F6 Q31013868-F191AF77-4489-40BA-8AD1-96CB5EF47570 Q33328474-DFDA5100-0214-403A-BC5C-819694B658E6 Q33602561-2FDB84D0-8AA2-4A19-A8F8-D5EEF1F2A9A2 Q33751509-8671B911-6468-439A-B7A2-609575B6FEEC Q33754371-652036D5-CD2F-4D28-9C5C-762F4297DD37 Q33761365-04331209-1F45-4838-9748-1F43AC1655B6 Q33892987-940D3575-EA40-4151-9E69-CF1B039B1EA0 Q33975989-0B53E318-0077-4587-9573-38A6D32A5BA5 Q33980497-A46DD5B3-D728-48F9-9E6D-88AF29C2B634 Q34009446-BB97480A-FD54-45C2-A1CB-4720A43ECE5D Q34121516-88D645FD-EDBE-425B-B021-8D2A0FA52F2E Q34142180-C5A090C3-FC77-4FD5-AC3B-370614B3BEC5 Q34142491-60FA65A9-78E6-4BC1-9389-3AA384DCF321 Q34335217-9018E127-B192-4C20-BD32-C85CB961713B Q34518388-8AA35FA5-D106-45BE-9B5A-2F863C54F9BA Q34530881-5B7CA568-34F7-496C-B078-10FD2B26986B Q34531090-57990B25-2207-4A1F-AE76-1E6F2BFDD6CA Q34532590-0D369C74-891F-4F56-B3CC-59FE0C6DECE3 Q34563942-D2D87241-4E11-42D6-8D60-89A35C686629 Q34756259-51C8AF4C-5188-4605-B7AB-C3924DB7CDE1 Q35098810-9F86E6A5-DBE8-40D0-8E13-783B8B5AD23C Q35114601-689B1242-DDC2-4BE8-85D1-53774AAC047E Q35116225-19ADEA60-0306-4183-AF7A-C2E54EB2EDCA Q35124388-4E61BBB3-B96A-4DA6-93D3-02938F12FE5D Q35127872-6E622BBF-FB72-45DF-8D70-A0436568DCAF Q35132244-92133010-6F5D-47C3-9234-D1572869386F Q35154642-989CBD02-E5D6-4D2B-8FF2-A866D01AEB61 Q35172081-09F5E3CF-171E-4D79-B5ED-133192863ABA Q35205054-EC1AACB4-62B0-43A3-A8D4-07699A853C04

P2860

Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

http://www.wikidata.org/entity/Q48379750

description

1986 nî lūn-bûn

@nan

1986年の論文

@ja

1986年学术文章

@wuu

1986年学术文章

@zh

1986年学术文章

@zh-cn

1986年学术文章

@zh-hans

1986年学术文章

@zh-my

1986年学术文章

@zh-sg

1986年學術文章

@yue

1986年學術文章

@zh-hant

name

Cryptococcal disease in patien ...... ures and outcome of treatment.

@en

Cryptococcal disease in patien ...... ures and outcome of treatment.

@nl

type

label

Cryptococcal disease in patien ...... ures and outcome of treatment.

@en

Cryptococcal disease in patien ...... ures and outcome of treatment.

@nl

prefLabel

Cryptococcal disease in patien ...... ures and outcome of treatment.

@en

Cryptococcal disease in patien ...... ures and outcome of treatment.

@nl

P1433

Q48379750-D67A6B1A-C4AE-4688-9AF0-6378275F3273

P1476

Q48379750-DFE0FBEA-1DFF-4BDA-AF3C-122A9C1B381C

P2093

Q48379750-2450E85B-A53E-476A-88C8-702416551040

Q48379750-6EE6B564-2FB8-4416-BED6-D306FA5B6736

Q48379750-9B47665D-D317-4664-9ACD-F277DF9BA7B7

Q48379750-F40DFF44-8936-475B-948F-CE18A2048584

P304

Q48379750-A740A1A7-1A84-4F04-93B2-0C76F46D2E15

P31

Q48379750-B9519ECC-0192-452D-BA7A-5EFECD141B23

P356

Q48379750-68DF67F1-D7BB-4B0B-9C74-66E08D366D20

P407

Q48379750-2A583D4A-BEB0-4717-98DE-A4589AAFDB30

P433

Q48379750-7E071963-52D2-4CCE-8B2D-0565A7D7136E

P478

Q48379750-ED6962CB-6303-407A-9317-9FBA8752DF2D

P50

Q48379750-4FF03220-C025-4818-AA49-FFE781842086

P577

Q48379750-4CC6BEC3-8092-4A1A-93E1-EB08C131A12E

P698

Q48379750-73D454A3-14B2-4FFB-BAEE-30408C4DB102

P921

Q48379750-55DCDB8E-F178-4C4D-81EB-1F479EE7858F

Q48379750-b99d47fd-b5e3-4bce-8fe1-2c6d1fa941cc

P356

0003-4819-104-2-234

P1433

Annals of Internal Medicine

P1476

Cryptococcal disease in patien ...... ures and outcome of treatment.

@en

P2093

Holzman RS

http://www.w3.org/2001/XMLSchema#string

Rahal JJ

http://www.w3.org/2001/XMLSchema#string

Simberkoff MS

http://www.w3.org/2001/XMLSchema#string

Zuger A

http://www.w3.org/2001/XMLSchema#string

P304

234-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-104-2-234

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

P577

1986-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

3946951

http://www.w3.org/2001/XMLSchema#string

P921